AveXis (NASDAQ:AVXS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company’s product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. “
Several other analysts also recently commented on the company. Bank of America dropped their price objective on AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Chardan Capital reaffirmed a “buy” rating on shares of AveXis in a research note on Thursday, November 2nd. Canaccord Genuity initiated coverage on AveXis in a research note on Thursday, October 26th. They set a “hold” rating and a $110.00 price objective on the stock. Royal Bank of Canada raised their price objective on AveXis from $92.00 to $97.00 and gave the stock a “sector perform” rating in a research note on Friday, November 10th. Finally, BidaskClub cut AveXis from a “hold” rating to a “sell” rating in a report on Thursday, December 14th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have given a buy rating to the company’s stock. AveXis currently has an average rating of “Buy” and an average price target of $111.94.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same period last year, the business earned ($0.87) earnings per share. equities analysts forecast that AveXis will post -6.23 EPS for the current fiscal year.
In other news, insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $109.75, for a total value of $1,646,250.00. Following the completion of the transaction, the insider now owns 1,808,386 shares in the company, valued at approximately $198,470,363.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $109.72, for a total value of $195,301.60. Following the completion of the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at approximately $195,301.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,340 shares of company stock valued at $5,318,845. Corporate insiders own 18.60% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. California Public Employees Retirement System bought a new position in shares of AveXis in the 3rd quarter valued at about $570,000. Cubist Systematic Strategies LLC grew its holdings in shares of AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after acquiring an additional 1,577 shares in the last quarter. Highbridge Capital Management LLC bought a new position in shares of AveXis in the 3rd quarter valued at about $967,000. Perceptive Advisors LLC grew its holdings in shares of AveXis by 147.5% in the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock valued at $64,923,000 after acquiring an additional 400,000 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock valued at $99,363,000 after acquiring an additional 352,456 shares in the last quarter. Institutional investors own 92.88% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.themarketsdaily.com/2018/01/09/avexis-avxs-upgraded-to-hold-at-zacks-investment-research.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.